András M Komáromy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6627974/publications.pdf

Version: 2024-02-01

76 papers 2,757 citations

218592 26 h-index 50 g-index

76 all docs

76 docs citations

76 times ranked 2295 citing authors

#	Article	IF	CITATIONS
1	Use of extended protocols with nonstandard stimuli to characterize rod and cone contributions to the canine electroretinogram. Documenta Ophthalmologica, 2022, 144, 81-97.	1.0	3
2	Atypical chorioretinal lesions in Siberian Husky dogs with primary angle-closure glaucoma: a case series. BMC Veterinary Research, 2022, 18, 182.	0.7	0
3	Quantitative and qualitative characterization of retinal dystrophies in canine models of inherited retinal diseases using spectral domain optical coherence tomography (SD-OCT). Experimental Eye Research, 2022, 220, 109106.	1.2	1
4	Outer retinal thickness and visibility of the choriocapillaris in four distinct retinal regions imaged with spectral domain optical coherence tomography in dogs and cats. Veterinary Ophthalmology, 2022, 25, 122-135.	0.6	3
5	Intraocular pressure measurements using the TONOVET [®] rebound tonometer: Influence of the probeâ€cornea distance. Veterinary Ophthalmology, 2021, 24, 175-185.	0.6	9
6	Prophylactic antiâ€glaucoma therapy in dogs with primary glaucoma: A practitioner survey of current medical protocols. Veterinary Ophthalmology, 2021, 24, 96-108.	0.6	10
7	Safety and efficacy of topically administered netarsudil (Rhopressaâ"¢) in normal and glaucomatous dogs with ADAMTS10 â€openâ€angle glaucoma (ADAMTS10 â€OAG). Veterinary Ophthalmology, 2021, 24, 75-	36 ^{0.6}	10
8	Looking into the future: Gene and cell therapies for glaucoma. Veterinary Ophthalmology, 2021, 24, 16-33.	0.6	20
9	Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases. Veterinary Ophthalmology, 2021, 24, 229-239.	0.6	5
10	Safety and efficacy of topically administered netarsudilâ€latanoprost fixed dose combination (FDC;) Tj ETQq0 0 C Veterinary Ophthalmology, 2021, 24, 610-619.	rgBT /Ov	erlock 10 Tf 5 1
11	Transconjunctival excision of an orbital conjunctival cyst using computerâ€assisted 3â€D surgical planning in a dog. Clinical Case Reports (discontinued), 2021, 9, e04345.	0.2	3
12	Biomechanics of the optic nerve head and sclera in canine glaucoma: A brief review. Veterinary Ophthalmology, 2021, 24, 316-325.	0.6	4
13	CNGB3 Missense Variant Causes Recessive Achromatopsia in Original Braunvieh Cattle. International Journal of Molecular Sciences, 2021, 22, 12440.	1.8	4
14	Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®). BMC Veterinary Research, 2021, 17, 366.	0.7	2
15	Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy. Molecular Therapy, 2020, 28, 266-278.	3.7	56
16	Feline postâ€sterilization hyphema. Veterinary Ophthalmology, 2020, 23, 588-591.	0.6	1
17	CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?. Molecular Therapy, 2020, 28, 706-708.	3.7	3
18	Use of 3-dimensional printing in surgical exploration of a nasolacrimal duct obstruction in a dog. Canadian Veterinary Journal, 2020, 61, 129-134.	0.0	1

#	Article	IF	CITATIONS
19	The future of canine glaucoma therapy. Veterinary Ophthalmology, 2019, 22, 726-740.	0.6	44
20	Primary angle-closure glaucoma with goniodysgenesis in a Beagle dog. BMC Veterinary Research, 2019, 15, 75.	0.7	6
21	<i>BEST1</i> gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2839-E2848.	3.3	62
22	Successful chemical ablation of an intraorbital cyst caused by an eyelid injury and iatrogenic ankyloblepharon formation in a duck. Journal of the American Veterinary Medical Association, 2018, 253, 1164-1168.	0.2	1
23	Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in <i>CNGB3</i> Human Gene Therapy Clinical Development, 2017, 28, 197-207.	3.2	20
24	Assessment of Rod, Cone, and Intrinsically Photosensitive Retinal Ganglion Cell Contributions to the Canine Chromatic Pupillary Response., 2017, 58, 65.		23
25	An intronic LINE-1 insertion in MERTK is strongly associated with retinopathy in Swedish Vallhund dogs. PLoS ONE, 2017, 12, e0183021.	1.1	10
26	Influence of Age on Ocular Biomechanical Properties in a Canine Glaucoma Model with ADAMTS10 Mutation. PLoS ONE, 2016, 11, e0156466.	1.1	33
27	Novel retinopathy in related Gordon setters: a clinical, behavioral, electrophysiological, and genetic investigation. Veterinary Ophthalmology, 2016, 19, 398-408.	0.6	5
28	Sudden acquired retinal degeneration syndrome (<scp>SARDS</scp>) â€" a review and proposed strategies toward a better understanding of pathogenesis, early diagnosis, and therapy. Veterinary Ophthalmology, 2016, 19, 319-331.	0.6	32
29	Changes in posterior scleral collagen microstructure in canine eyes with an ADAMTS10 mutation. Molecular Vision, 2016, 22, 503-17.	1.1	9
30	A Novel Genome-Wide Association Study Approach Using Genotyping by Exome Sequencing Leads to the Identification of a Primary Open Angle Glaucoma Associated Inversion Disrupting ADAMTS17. PLoS ONE, 2015, 10, e0143546.	1.1	28
31	Dog Models for Blinding Inherited Retinal Dystrophies. Human Gene Therapy Clinical Development, 2015, 26, 15-26.	3.2	50
32	Genetics of Canine Primary Glaucomas. Veterinary Clinics of North America - Small Animal Practice, 2015, 45, 1159-1182.	0.5	24
33	A Novel Form of Progressive Retinal Atrophy in Swedish Vallhund Dogs. PLoS ONE, 2014, 9, e106610.	1.1	19
34	A Novel Missense Mutation in ADAMTS10 in Norwegian Elkhound Primary Glaucoma. PLoS ONE, 2014, 9, e111941.	1.1	34
35	Increased Expression of MERTK is Associated with a Unique Form of Canine Retinopathy. PLoS ONE, 2014, 9, e114552.	1.1	7
36	Do Acidic Residues in the Tri-Asp Motif of the CNGA3 S2 Domain Form Required Pairings with Positive Residues of the S1-S4 Bundle? Evidence from Day-Blind Dogs and Insights from a Molecular Model of CNGA3 S1-S6 with Md Simulations. Biophysical Journal, 2014, 106, 759a.	0.2	0

#	Article	IF	Citations
37	A golden retriever with bilateral blepharospasm and ocular discharge. Lab Animal, 2014, 43, 127-130.	0.2	O
38	A Cyclic Nucleotide-Gated Channel Mutation Associated with Canine Daylight Blindness Provides Insight into a Role for the S2 Segment Tri-Asp motif in Channel Biogenesis. PLoS ONE, 2014, 9, e88768.	1.1	10
39	Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. BMC Genetics, 2013, 14, 27.	2.7	25
40	Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E517-25.	3.3	401
41	Guidelines for clinical electroretinography in the dog: 2012 update. Documenta Ophthalmologica, 2013, 127, 79-87.	1.0	58
42	Monitoring CNGA3 and CNGB3 Subunit Expression in Retinas of Day-Blind Canines with Inherited Deletion or Missense CNGB3 Asp262Asn Mutations Show Progressive Loss of Both CNGB3 and CNGA3 Expression. Biophysical Journal, 2013, 104, 280a.	0.2	0
43	Transient Photoreceptor Deconstruction by CNTF Enhances rAAV-Mediated Cone Functional Rescue in Late Stage CNGB3-Achromatopsia. Molecular Therapy, 2013, 21, 1131-1141.	3.7	74
44	Investigating the inheritance of prolapsed nictitating membrane glands in a large canine pedigree. Veterinary Ophthalmology, 2013, 16, 416-422.	0.6	13
45	Tapetal dysplasia in a Swedish Vallhund dog. Veterinary Ophthalmology, 2013, 16, 145-150.	0.6	2
46	Biomechanical Properties and Correlation With Collagen Solubility Profile in the Posterior Sclera of Canine Eyes With an <i>ADAMTS10</i> Mutation., 2013, 54, 2685.		24
47	Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects. PLoS ONE, 2013, 8, e75666.	1.1	48
48	Exclusion of <i>RPGRIP1</i> ii>ins44 from Primary Causal Association with Early-Onset Cone–Rod Dystrophy in Dogs. , 2012, 53, 5486.		18
49	Preface. Veterinary Ophthalmology, 2012, 15, 1-2.	0.6	O
50	Equine Multiple Congenital Ocular Anomalies (MCOA) syndrome in <i>PMEL17</i> (<i>Silver</i>) mutant ponies: five cases. Veterinary Ophthalmology, 2011, 14, 313-320.	0.6	38
51	Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Veterinary Ophthalmology, 2010, 13, 294-300.	0.6	75
52	Gene therapy rescues cone function in congenital achromatopsia. Human Molecular Genetics, 2010, 19, 2581-2593.	1.4	235
53	Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. American Journal of Veterinary Research, 2010, 71, 97-102.	0.3	31
54	Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. Journal of the American Veterinary Medical Association, 2010, 236, 73-73.	0.2	0

#	Article	IF	CITATIONS
55	Operating in the Dark. JAMA Ophthalmology, 2008, 126, 714.	2.6	12
56	Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer. Molecular Therapy, 2008, 16, 458-465.	3.7	236
57	Effects of the topically applied calcium-channel blocker flunarizine on intraocular pressure in clinically normal dogs. American Journal of Veterinary Research, 2008, 69, 273-278.	0.3	8
58	Canine and Human Visual Cortex Intact and Responsive Despite Early Retinal Blindness from RPE65 Mutation. PLoS Medicine, 2007, 4, e230.	3.9	107
59	Application of a New Subretinal Injection Device in the Dog. Cell Transplantation, 2006, 15, 511-519.	1.2	32
60	Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital Amaurosis. Human Gene Therapy, 2006, 17, 845-858.	1.4	142
61	Effect of head position on intraocular pressure in horses. American Journal of Veterinary Research, 2006, 67, 1232-1235.	0.3	77
62	Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal Injection. Molecular Therapy, 2006, 13, 1074-1084.	3.7	196
63	881. Safety, Efficacy and Biodistribution of Recombinant AAV2-RPE65 Vector Delivered by Ocular Subretinal Injection. Molecular Therapy, 2006, 13, S339.	3.7	0
64	Equine amniotic membrane transplantation for corneal ulceration and keratomalacia in three horses. Veterinary Ophthalmology, 2005, 8, 311-317.	0.6	64
65	Functional and Structural Analysis of the Visual System in the Rhesus Monkey Model of Optic Nerve Head Ischemia., 2004, 45, 1830.		24
66	Hypertensive retinopathy and choroidopathy in a cat. Veterinary Ophthalmology, 2004, 7, 3-9.	0.6	16
67	Optic nerve head morphology of the Eastern gray squirrel, Sciurus carolinensis. Veterinary Ophthalmology, 2004, 7, 169-173.	0.6	0
68	Periocular sarcoid in a horse. Veterinary Ophthalmology, 2004, 7, 141-146.	0.6	17
69	Passive attenuation of cortical pattern evoked potentials with increasing body weight in young male rhesus macaques. Documenta Ophthalmologica, 2003, 106, 231-238.	1.0	1
70	Flash electroretinography in standing horses using the DTLâ,,¢ microfiber electrode. Veterinary Ophthalmology, 2003, 6, 27-33.	0.6	35
71	The effect of an I-type calcium channel blocker on the hemodynamics of orbital arteries in dogs. Veterinary Ophthalmology, 2003, 6, 141-146.	0.6	17
72	Evaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. American Journal of Veterinary Research, 2003, 64, 1081-1087.	0.3	80

#	Article	IF	CITATIONS
73	Long-Term Effect of Retinal Ganglion Cell Axotomy on the Histomorphometry of Other Cells in the Porcine Retina. Journal of Glaucoma, 2003, 12, 307-315.	0.8	19
74	Endothelin 1 Levels in the Aqueous Humor of Dogs With Glaucoma. Journal of Glaucoma, 2002, 11, 105-109.	0.8	61
75	Technical issues in electrodiagnostic recording. Veterinary Ophthalmology, 2002, 5, 85-91.	0.6	18
76	Dog Models for Blinding Inherited Retinal Degenerations. Human Gene Therapy Clinical Development, 0, , 150127063140004.	3.2	0